CenterBook Partners LP Has $2.59 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

CenterBook Partners LP trimmed its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 472,075 shares of the company's stock after selling 218,002 shares during the period. CenterBook Partners LP owned about 0.30% of Xeris Biopharma worth $2,592,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at $34,000. Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma during the 4th quarter valued at $44,000. Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma during the 4th quarter valued at $45,000. Two Sigma Advisers LP acquired a new position in Xeris Biopharma in the 4th quarter worth $47,000. Finally, Aquatic Capital Management LLC acquired a new position in Xeris Biopharma in the 4th quarter worth $50,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch purchased 25,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the acquisition, the insider directly owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.47% of the stock is owned by corporate insiders.

Xeris Biopharma Stock Performance

NASDAQ XERS traded down $0.12 during midday trading on Friday, hitting $5.11. The company had a trading volume of 1,480,498 shares, compared to its average volume of 2,077,846. The firm has a fifty day simple moving average of $4.79 and a two-hundred day simple moving average of $4.36. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Oppenheimer upped their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen lowered shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Xeris Biopharma presently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.